Use of Metabolic Markers To Identify Overweight Individuals Who Are Insulin Resistant

Tracey McLaughlin, Fahim Abbasi, Karen Cheal, +3

Annals of Internal Medicine

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó, +201

The Lancet

Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseMedicineInsulin Management +7

Discrimination Between Obesity and Insulin Resistance in the Relationship With Adiponectin

Fahim Abbasi, James W. Chu, Cindy Lamendola, +4

Diabetes

Successful Long-Term Treatment of Refractory Cushing’s Disease with High-Dose Mifepristone (RU 486)

James W. Chu, Dwight F. Matthias, Joseph K. Belanoff, +3

The Journal of Clinical Endocrinology & Metabolism

High Prevalence of Autoimmune Thyroid Disease in Pulmonary Arterial Hypertension

James W. Chu, Peter N. Kao, John L. Faul, +1

CHEST Journal

HypertensionPulmonary Arterial HypertensionAllergyAutoimmune DiseaseThyroid Disease +7

Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus

Fahim Abbasi, James W. Chu, Tracey McLaughlin, +3

Metabolism

Metabolic SyndromeDiabetes ManagementHealth PolicyCardiovascular DiseaseDiabetes +7

Insulin resistance in idiopathic dilated cardiomyopathy

Ronald Witteles, W.H. Wilson Tang, Aamer Jamali, +3

Journal of the American College of Cardiology

Insulin ResistanceMetabolic SyndromeCardiomyopathyHeart FailureInsulin Signaling +7

Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes

Fahim Abbasi, Sang-Ah Chang, James W. Chu, +5

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology

Metabolic DisorderPlasma AdiponectinCaloric RestrictionInsulin SignalingObesity +16

Rosiglitazone Reduces Glucose-Stimulated Insulin Secretion Rate and Increases Insulin Clearance in Nondiabetic, Insulin-Resistant Individuals

Sun H. Kim, Fahim Abbasi, James W. Chu, +4

Diabetes

Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia

Cindy Lamendola, Fahim Abbasi, James W. Chu, +6

The American Journal of Cardiology

Metabolic SyndromeLipid DisorderDiabetes ManagementLipid MetabolismCardiovascular Disease +8